Metabolic markers have prognostic value in AML,28 and metabolic targeting is considered a possible therapeutic strategy.29 Our present observations suggest that the antileukemic effects of various strategies for metabolic targeting differ between patient subsets identified by analysis of PI3K-Akt-mTOR activation. The gene discussed is MTOR; the disease is acute myeloid leukemia.